Adjuvant chemotherapy for completely resected non-small-cell lung cancer.

  title={Adjuvant chemotherapy for completely resected non-small-cell lung cancer.},
  author={Hiroshi Suehisa and Shinichi Toyooka},
  journal={Acta medica Okayama},
  volume={63 5},
For many years, surgery alone was the standard treatment for patients with stage I-IIIA non-small-cell lung cancer (NSCLC). However, recent studies have demonstrated that adjuvant chemotherapy provides a survival benefit. The first adjuvant chemotherapy for NSCLC was performed in the 1960s using a key drug known as cyclophosphamide. In the 1980s and early 1990s, a new anti-cancer drug, cisplatin, was developed. The first meta-analysis of this drug was conducted by the Non-small Cell Lung Cancer… CONTINUE READING


Publications citing this paper.
Showing 1-9 of 9 extracted citations


Publications referenced by this paper.
Showing 1-10 of 35 references

Long-term results of the International Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer (NSCLC)

  • TL Chevalier, A Dunant, +7 authors Group IALT Collaborative
  • J Clin Oncol (2008) 26: 398s
  • 2008
1 Excerpt

Surgery and adjuvant chemotherapy (CT) compared to surgery alone in non-small cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomized clinical trials (RCT)

  • LA Stewart, S Burdett, JF Tierney, J Pignon, Group on behalf of the NSCLC Collaborative
  • J Clin Oncol (2007) 25: 397s
  • 2007
2 Excerpts

Similar Papers

Loading similar papers…